Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liraglutide Clear all
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

NCT03757130
View directory record Official record
Conditions
Obesity
Interventions
AMG 598, Placebo, Liraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NCT01511185
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

NCT01272219
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

Lifestyle Modification and Liraglutide

NCT02911818
View directory record Official record
Conditions
Obesity
Interventions
CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling
Behavioral · Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

NCT02235961
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 26, 2026, 10:43 AM EDT
Terminated Phase 4 Interventional

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531
View directory record Official record
Conditions
Type 2 Diabetes, Gastric Banding
Interventions
Liraglutide, Orlistat, Liraglutide + Orlistat
Drug
Lead sponsor
East Carolina University
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Results available

A Study of Tirzepatide in Overweight and Very Overweight Participants

NCT04311411
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo, Liraglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 26, 2026, 10:43 AM EDT
Enrolling by invitation No phase listed Observational

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

NCT07640139
View directory record Official record
Conditions
Obesity
Interventions
Incretin-based therapies (GLP-1 and GLP-1/GIP)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
125,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 26, 2026, 10:43 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

NCT01722227
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

NCT00943501
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Cypress, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 26, 2026, 10:43 AM EDT
Not listed Phase 4 Interventional

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

NCT02344186
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 26, 2026, 10:43 AM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 26, 2026, 10:43 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 26, 2026, 10:43 AM EDT
Recruiting Phase 4 Interventional

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892
View directory record Official record
Conditions
Type2Diabetes, ASCVD
Interventions
SGLT2 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
36
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 26, 2026, 10:43 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

NCT04575844
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Liraglutide, Exercise training, Liraglutide + Exercise training
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

NCT02014740
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

NCT03480022
View directory record Official record
Conditions
Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
Interventions
Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 26, 2026, 10:43 AM EDT
Completed No phase listed Observational Results available

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

NCT05073692
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
241,981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

NCT02960659
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

NCT02773368
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Glendale, Arizona • La Jolla, California • Mission Viejo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 26, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 26, 2026, 10:43 AM EDT